secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2021-10-12T23:59:59+00:00
Accession:  0001213900-21-052291
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus Life Sciences licenses IRAK4 inhibitor KM10544 from Kainos for cancer treatment
--------------------------------------------------------------------------------

- Exclusive license for U.S., U.K., EU to Kainos' IRAK4 inhibitor KM10544 for cancers including leukemia, lymphoma, solid tumors.
- Six-figure upfront cash payment; mid-eight-figure milestones; single-digit royalty on net sales; similar sublicensing fee.
- Emmaus plans in-vivo studies, IND-enabling studies, and seeks Orphan Drug Designation.
- Agreement expands existing R&D collaboration between Emmaus and Kainos.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390021052291/0001213900-21-052291-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390021052291/ea148129-8k_emmanus.htm
  HTML page:      https://secwatch.observer/filing/0001213900-21-052291

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer